Against notice was appetite stimulants Therapeutics and combines two drugs - naltrexone and bupropion. Bupropion is used to treat depression and addiction to smoking, while naltrexone is already in the treatment of addiction of opium withdrawal.
"Contrave is designed to activate a hypothalmic center in the brain associated with reduced appetite, while blocking beta-endorphin, which may be responsible for limiting weight loss. We are also studying the effects of Contrave on related central pathways associated with the rewarding nature of select high calorie foods."
Contrave is a fixed dose combination of Bupropion SR (sustained release) and tasty new formulation of naltrexone SR in a single tri-layer tablet. Raves container is designed to act on neurons in the brain with the aim of achieving appetite suppression, decreased food thirst, weight loss and sustainable.
Contrave raves in the three arms, the average decrease of visceral fat ranged from 13.7% to 16.7% after 24 weeks of treatment compared to an average reduction of 4.6% between the placebo group. In addition, the effect of Cont raves was significantly higher than that observed with one of the raves Cont individual components when administered alone. Visceral fat is located inside the abdominal cavity and around vital organs like the liver. Visceral fat accumulation, as opposed to subcutaneous fat that lies just below the skin is associated with an increased risk of cardiovascular disease and type II diabetes.
Tuesday, July 21, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment